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To investigate the role of microRNAs in the development of chemoresistance and related epithelial–
mesenchymal transition (EMT), we examined the effect of miR-489 in adriamycin (ADM)-resistant
human breast cancer cells (MCF-7/ADM). MiR-489 was signiﬁcantly suppressed in MCF-7/ADM cells
compared with chemosensitive parental control MCF-7/WT cells. Forced-expression of miR-489
reversed chemoresistance. Furthermore, Smad3 was identiﬁed as the target of miR-489 and is highly
expressed in MCF-7/ADM cells. Forced expression of miR-489 both inhibited Smad3 expression and
Smad3 related EMT properties. Finally, the interactions between Smad3, miR-489 and EMT were
conﬁrmed in chemoresistant tumor xenografts and clinical samples, indicating their potential
implication for treatment of chemoresistance.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the leading cause of cancer death among
females. Chemotherapy is frequently used for breast cancer treat-
ment, but the major impediment to success is the development
of chemoresistance [1–3].
Various factors may cause chemoresistance, and recent studies
have indicated that epithelial–mesenchymal transition (EMT) is
intensively involved. EMT is an important process that plays key
roles in embryonic development, as well as in cancer and other dis-
eases [4–7]. During the acquisition of EMT characteristics, epithe-
lial cells gain mesenchymal features by losing polarity and cell–
cell contacts, together with dramatic remodeling of the cytoskele-
ton [8], a process that endows the epithelial cells with high motil-
ity. Cancer epithelial cells have been found to hijack the EMT
pathways to develop chemoresistance [9,10]. Cancer cells are able
to manipulate the expression of genes that activate the EMT
process, such as decreasing the expression of E-cadherin (E-cad),
as well as increasing the expression of vimentin (VIM) andN-cadherin. The EMT process provides cancer cells with enhanced
abilities for migration and invasion [11,12]. The increase of cell
motility by the EMT process thus enables cancers to be resistant
to anoikis, as well to escape from immune surveillance and
chemotherapeutic drugs, ﬁnally developing chemoresistance and
inducing metastasis [13,14]. Therefore, the development of EMT
inhibitors may provide novel strategies for the prevention,
diagnosis, and treatment of cancers.
MicroRNAs (miRNAs) constitute another important factor in the
development of chemoresistance in cancer cells [15,16]. MiRNAs
are endogenously-expressed non-coding RNAs that target the
30untranslated regions (30UTRs) of mRNAs for cleavage or the inhi-
bition of translation [17]. Recent studies have shown that miRNAs
interact intensively with EMT to develop chemoresistance. Bryant
et al. [18] identiﬁed 13 miRNAs that participate in the develop-
ment of chemoresistance to anti-epidermal growth factor receptor
(EGFR) therapy in non-small-cell lung cancer cells; these miRNAs
are also involved in EMT signaling in cancer cells. Among those
miRNAs, miR-200c (or the miR-200 family) is one of the most
extensively studied miRNAs associated with both chemoresistance
and EMT in various kinds of cancer cells [19].
However, to date the list of miRNAs linked both to EMT and che-
moresistance is small and the underlying mechanisms remain
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related chemoresistance in breast cancer cells. MiR-489 was
down-regulated in adriamycin (ADM)-resistant human breast can-
cer cells (MCF-7/ADM) compared with parental control cells (MCF-
7/WT). Re-expression of miR-489 reversed the chemoresistance
and EMT features of these cells by targeting Smad3. In xenograft
tumors and clinical samples, Smad3, miR-489, and EMT biomark-
ers were correlated with chemoresistance. Our novel ﬁndings pro-
vide a potential target to overcome chemoresistance by miRNA via
the EMT pathway.
2. Materials and methods
2.1. Ethics statement
All animal experiments were performed in accordance with the
laboratory animal guidelines and with approval from the Animal
Experimentations Ethics Committee, Jiangnan University. The
study using clinical samples was approved by Institutional Review
Board at the afﬁliated hospital, Jiangnan University.
2.2. Cell culture and reagents
MCF-7/WT (human breast cancer) cells were purchased from
the ATCC. Adriamycin (ADM)-resistant (MCF-7/ADM) cells were
derived by treating MCF-7/WT cells with stepwise increasing con-
centrations of ADM over 8 months. All cells were maintained in
RPMI-1640 (Gibco, USA) supplemented with 10% fetal bovine
serum (FBS) with 100 U/ml penicillin and 0.1 mg/ml streptomycin
and 0.01 mg/ml insulin at 37 C in a humidiﬁed atmosphere of
5% CO2.
Agomir-489 that mimics endogenous miR-489 was from Ribo-
Bio Co., Ltd. (Guangzhou, China). The antibodies used for immuno-
ﬂuorescence staining and western blot analyses were as follows:
antibody against E-cadherin (R&D, USA), vimentin, Smad3 (Abcam,
USA), horseradish peroxidase-conjugated secondary antibody
(Beyotime, China), and Alexa Fluor 488 and Alexa Fluor 546
secondary antibody (Invitrogen, USA).
2.3. Clinical samples collection and in situ hybridization (ISH) of
miRNA
All procedures were conducted with the approval of the Ethics
Committees of the University and the Hospital. Tissue samples
were collected from breast cancer patients in The Afﬁliated Hospi-
tal of Jiangnan University (Wuxi, China). Samples were embedded
in TissueTek OCT (Sakura, Japan) and stored at 80 C.
In situ hybridization (ISH) was performed using the locked
nucleic acid (LNA)-modiﬁed oligonucleotide probe (Biolink, China).
Fixed cultured cells, slides, and surgical specimens were washed
with 0.1 mM PBS, permeabilized with 0.4% Triton X-100, and trea-
ted with 1 lg/ml proteinase K (Beyotime, China). The cells were
then washed with 4% (m/v) paraformaldehyde for 5 min to inhibit
the effects of the proteinase. To reduce non-speciﬁc signals, cells
were washed once with 0.25% acetic anhydride. Hybridization with
the probe (20 nM) was carried out at 54 C for 16 h after incubation
in 50% formamide that had been deionized for 30 min at 37 C. The
cells were washed once with 4 SSC for 15 min at 37 C, and once
with NTE buffer (500 mM NaCl, 10 mM Tris, 1 mM EDTA, 20 lg/ml
RNase A) for 30 min at 37 C to digest the single-stranded RNA,
then rinsed once with 1 SSC and 0.5 SSC (15 min each) at
37 C, and ﬁnally washed twice with Buffer 1 (100 mM Tris,
150 mM NaCl, pH 7.5) for 10 min. All ISH images of miR-489 were
captured by a confocal laser scanning microscope (Leica TCS SP8,
Germany).2.4. Transfection of miRNA
MCF-7/ADM cells were resuspended in Opti-MEM I medium
(Invitrogen, USA) with 400 nM agomir-489 (mimic) or agomir-con-
trol (negative control). After incubation at 37 C under 5% CO2 for
6 h, RPMI 1640 supplemented with 10% FBS was added 3-fold
and cells were cultivated as described above. Then culture was
continued for 48 h for assay.
2.5. Reverse transcription and quantitative real-time PCR
Total RNA was prepared using Trizol (Beyotime, China) accord-
ing to the manufacturer’s instructions. A cDNA library was gener-
ated using a Reverse Transcriptase M-MLV (TaKaRa, Japan). The
cDNA was used for the ampliﬁcation of genes of E-cadherin,
vimentin and b-actin. The reverse transcription primer pairs for
E-cadherin (E-cad) were forward 50-gctggagattaatccggaca-30,
reverse 50-acccacctctaaggccatct-30, vimentin (VIM) were forward
50-ggctcagattcaggaacagc-30, reverse 50-gcttcaacggcaaagttctc-30,
b-actin were forward 50-tgtcaccaactgggacgata-30, reverse
50-tctcagctgtggtggtgaag-30.Reverse transcription data were ana-
lyzed with ImageJ software (NIH, USA), and b-actin was used as
an endogenous control. For mature miRNA quantiﬁcation, cDNA
was synthesized using Stem-loop RT primers and a Hairpin-it micr-
oRNA qPCR Quantitation Kit (GenePharma, China). U6 small
nuclear RNA (snRNA) was used as an internal control. The relative
expression level of miR-489 in each sample was calculated using
the comparative expression level 244Ct method [20] and normal-
ized to the expression of U6 snRNA. All qRT-PCRs were performed
in triplicate, and data are presented as mean ± standard error of the
mean (S.E.M.).
2.6. Western blot analysis
Whole-cell lysates of treated cells were prepared and separated
on 10% SDS–PAGE. Membranes were immunoblotted against
Smad3. The antigen–antibody complexes were visualized using
an enhance chemiluminescence detection system. The expression
of Samd3 was quantiﬁed by ImageJ software for gray value, and
normalized to b-actin.
2.7. Immunoﬂuorescence staining
Cells were ﬁxed with 4% (m/v) paraformaldehyde, permeabili-
zed with 0.1% TritonX-100, and blocked with 5% BSA. Then the
cells were stained with primary antibody and subsequently with
Alexa Fluor 488-conjugated donkey anti-mouse secondary anti-
body or Alexa Fluor 568-conjugated donkey anti-rabbit secondary
antibody (Invitrogen, USA). After staining, images were acquired
with a confocal laser scanning microscope (Leica TCS SP8,
Germany).
2.8. Migration assays
For motility assays, 105 cells were added to the top chamber of
uncoated PET membranes in 24-well Corning plates. Medium sup-
plemented with 10% FBS was added to the lower chamber of each
well as a chemoattractant. Cells were incubated for 48 h, and those
that did not migrate through the ﬁlter (on the upper surface) were
removed with a cotton swab. Cells that had migrated to the lower
surface of the ﬁlter were ﬁxed with 4% (m/v) paraformaldehyde
and stained with crystal violet. Migrated cells were counted under
a microscope. Images were captured by a video camera (Nikon
Coolpix 54, Japan) mounted on the microscope (Leica CME,
Germany).
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Twenty female nude mice (4–6 weeks old) were purchased
from model animal research center of Nanjing University (Nanjing,
China), housed under aseptic conditions, and cared for in
accordance with the guidelines of the Laboratory Animal Unit of
Jiangnan University. Tumor xenografts were established by
subcutaneous injecting MCF-7/WT or MCF-7/ADM cells into the
back ﬂanks of mice (5  106 cells per mouse). Tumor sizes were
measured every 3 days until reached 200 mm3.
2.10. Statistical analysis
Results are presented as mean ± S.E.M. Statistical differences
were determined by Student’s t-test. We performed statistics anal-
yses using Graphpad Prism 5.0 software. All statistical tests were
two-tailed, and a value of P < 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. MiR-489 is involved in chemoresistance in breast cancer cells
We established the MCF-7/ADM cell line as described in our
previous study [21,22]. MCF-7/ADM cells displayed a 630-fold
greater resistance to ADM than the parental line MCF-7/WT. In pre-
vious studies, we used high-throughput small-RNA sequencing to
compare MCF-7/WT and MCF-7/ADM cells (unpublished data)
and identiﬁed miR-489 was one of the most markedly changed
miRNAs. We then used qRT-PCR (Fig. 1A) and in situ hybridization
(ISH) (Fig. 1B) to validate the expression of miR-489; this
showed that miR-489 was signiﬁcantly down-regulated in
MCF-7/ADM cells compared to MCF-7/WT cells. With transfectionμ
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Fig. 1. miR-489 is down-regulated and involved in chemoresistance in breast cancer.
compared with MCF-7/WT cells; miR-489 expression was normalized to U6 snRNA. (B)
was down-regulated in MCF-7/ADM cells. (C) qRT-PCR showing the relative expression
negative control (Agomir-control). (D) Chemoresistance of MCF-7/ADM cells were revers
set as a negative control (Agomir-control).⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, determined bof agomir-489, which mimics endogenous miRNA, qRT-PCR
showed that MCF-7/ADM cells transfected with miR-489 agomir
expressed approximately 600-fold more miR-489 compared to
those transfected with negative controls (Fig. 1C). MTT assay
showed that after agomir-489 transfection, MCF-7/ADM cells
became more sensitive to ADM treatment (Fig. 1D), indicating
the potential of miR-489 to reverse drug resistance.
3.2. Smad3 is the target of miR-489
Smad3 was predicted as a potential target by TargetScan soft-
ware (www.targetscan.org) and the luciferase reporter assay was
used to verify the binding. The 30UTR region of Smad3 mRNA
was cloned into luciferase reporter vector (pLUC). HEK293T
cells were then transfected with miR-489 together with the
luciferase reporter vector and the luciferase activity was
assessed. The results demonstrated that miR-489 suppressed
the expression of luciferase and thus targeted the 30UTR of
Smad3 (Fig. 2A).
We then examined the interaction between Smad3 and miR-
489 in MCF-7/ADM cells. Western blot results showed that Smad3
was up-regulated in MCF-7/ADM cells compared to MCF-7/WT
cells (Fig. 2B), while forced expression of miR-489 in MCF-7/ADM
cells signiﬁcantly decreased Smad3 expression (Fig. 2C and D).
3.3. MiR-489 regulates EMT in breast cancer cells
Because Smad3 plays an important role in EMT [23,24], and we
found that MCF-7/ADM cells displayed mesenchymal-like markers,
such as the high expression of vimentin, the absence of E-cadherin,
and high migratory ability (Fig. 3A and B), suggesting EMT-like
features. We then investigated whether the down-regulation of
miR-489 was involved in the gaining of EMT properties. For this-489 DAPI miR-489/DAPI
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Fig. 2. Smad3 is a target of miR-489. (A) Luciferase reporter assay showing that the 30UTR of Smad3 mRNA was targeted by miR-489. (B) Western blots showing that Smad3
was upregulated in MCF-7/ADM cells. (C and D) Western blots and confocal immunostaining shows that Smad3 was down-regulated in MCF-7/ADM cells after miR-489 re-
expression.⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, determined by a two-sided t-test. Scale bars, 10 lm.
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Fig. 3. miR-489 regulates EMT in breast cancer. (A) Representative images showing the expression of EMT-related biomarkers in MCF-7/ADM cells by immunostaining. Cells
were stained with E-cadherin (green), vimentin (red), and DAPI (blue); images were captured at 63 oil magniﬁcation. (B) Transwell chamber images showing that migration
was signiﬁcantly increased in MCF-7/ADM cells; results were calculated as the number of cells that migrated in each well. (C) RT-PCR showing E-cadherin was up-regulated
and vimentin was down-regulated after miR-489 re-expression. (D) Representative immunostaining images showing the expression of EMT-related biomarkers in MCF-7/
ADM cells when miR-489 was re-expressed. Cells were stained as described in (A). (E) Restoration of miR-489 inhibited the migration of MCF-7/ADM cells.⁄P < 0.05, ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001, determined by a two-sided t-test. Scale bars, 10 lm.
2012 L. Jiang et al. / FEBS Letters 588 (2014) 2009–2015purpose, MCF-7/ADM cells were transfected with agomir-489, and
the results showed that restoring the activity of miR-489 decreased
the expression of vimentin and increased the expression ofE-cadherin at the RNA and protein levels (Fig. 3C and D). As a
result, miR-489 signiﬁcantly inhibited the migration of MCF-7/
ADM cells (Fig. 3E).
L. Jiang et al. / FEBS Letters 588 (2014) 2009–2015 20133.4. MiR-489 is associated with EMT features and chemotherapeutic
response in human breast tumor xenografts in athymic nude mice and
in clinical samples
After validating the gene/miRNA expression changes in MCF-7/
WT and MCF-7/ADM cells, we assessed gene/miRNA expression in
nude mice bearing MCF-7/WT and MCF-7/ADM xenograft tumors.
Immunohistochemistry showed low E-cadherin and abundant
vimentin (Fig. 4A) and Smad3 (Fig. 4B) in MCF-7/ADM xenograft
tumors compared with MCF-7/WT tumors. In situ hybridization
showed that miR-489 expression was lower in MCF-7/ADM
(Fig. 4B) than in MCF-7/WT xenograft tumors. These results corre-
spond to the gene/miRNA expression in cells.
To further verify our results, we assessed the expression and
correlation of miR-489, Smad3, E-cadherin, and vimentin in clinical
samples of breast cancers. Tissues from patient receiving anthracy-
cline–taxane-based neoadjuvant chemotherapy were collected.
Tumor masses of which the volume did not signiﬁcantly decrease
after neoadjuvant therapy (i.e. from non-responders) were consid-
ered to be chemoresistant. Post-chemotherapy samples were com-
pared to identify the gene/miRNA expression changes in
chemoresistant and chemosensitive cases. Results showed that
miR-489 was down-regulated, while Smad3 was up-regulated in
non-responders compared to responders (Fig. 5A). At the same
time, we found that low miR-489 expression and high-Smad3
expression were highly correlated with the EMT features of low
E-cadherin (Fig. 5B) and high vimentin expression in the samples
from non-responders.D
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ADM (adriamycin)-based chemotherapy is one of the standard
protocols for treating breast cancers, but ADM resistance occurs
often and results in failure. It is becoming increasingly evident that
miRNAs are critical modulators of chemoresistance and EMT in
many types of cancers. A few reports have revealed roles of miR-
NAs in ADM resistance, in which EMT was also implicated. For
example, Chen et al. [25] reported that an EMT modulator, miR-
200c, is down-regulated in ADM-resistant MCF-7 cells by inter-
rupting the normal expression of p-glycoprotein (p-gp), which is
a well-known membrane protein that pumps out chemotherapeu-
tic drugs [26]. More recently, it was shown that miR-34a modu-
lates the chemosensitivity of breast cancer cells to ADM by
targeting Notch1 [27], which is a key activator in the EMT pathway
[28]. However, none of these studies clearly addressed the co-reg-
ulation of EMT and ADM-resistance by miRNAs. Furthermore,
because both EMT and miRNAs are essential for the development
of chemoresistance, it is important to ﬁnd more miRNAs involved
in both chemoresistance and EMT in cancer cells.
We found that miR-489 was down-regulated in MCF-7/ADM
compared with MCF-7/WT cells, and that restoring its activity
decreased the chemoresistance, suggesting a role of miR-489 in
chemoresistance. MiR-489 has already been reported to be
down-regulated in squamous cell carcinoma. A recent study by
Kikkawa et al. [29] described the tumor-suppressive effects of
miR-489 in squamous cell carcinoma, where they showed that
miR-489 inhibited cell growth in all head and neck cancer cell-aft tumors  
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2014 L. Jiang et al. / FEBS Letters 588 (2014) 2009–2015lines examined. However, we are the ﬁrst to reveal the role of miR-
489 in chemoresistance to ADM.
In a search for potential targets of miR-489 that might be
involved in the resistance to ADM and the EMT-like phenotype in
MCF-7/ADM cells, we identiﬁed Smad3 as a candidate gene. MiR-
489 directly targeted Smad3, in that down-regulation of miR-489
expression led to high expression of Smad3 in MCF-7/ADM cells.
Smad3 has been shown in a number of studies to be involved in
EMT progression [30]. Smad3 was found to be critical for
TGF-b-induced EMT and can mediate the invasion of mammary
epithelium [31]. In response to TGF-b, Smad3 is essential to facili-
tate the function of Snail1 by forming a complex with it, the com-
plex then plays as a transcriptional repressor in EMT signaling and
directly targets the E-cadherin expression [32]. It was already
extensively found interrupting the Snail1 pathway effectively
affected the EMT pathway [33], so activation of Smad3 by miR-
489 must increase EMT, and then inhibit chemoresistance. Indeed,
in our model of MCF-7/ADM cells, which displayed some mesen-
chymal features and high expression of Smad3, we found that dis-
turbing the high activity of Smad3 by restoring the miR-489
activity not only reduced the chemoresistance, but also decreased
the EMT features, including (1) an enhanced expression of
E-cadherin which is a proved target of Smad3 [32], the increase
in E-cadherin fastened the cell–cell contact of epithelial MCF-7/
ADM cells and decreased their migration; (2) a losing of vimentin
which is a major cytoskeletal component of mesenchymal cells,
diminished vimentin changed mesenchymal cell shape and motil-
ity, as well as decreased the migration [34]. Therefore, our data
suggest the miR-489–Smad3 signaling pathway mediates chemo-
resistance to ADM through EMT.To further conﬁrm our results, we constructed a xenograft
model of nudemice to study the EMT features, miR-489, and Smad3
expression in human breast tumor xenografts. EMT markers and
Smad3 expression were found together with low miR-489 in
MCF-7/ADM xenograft tumors, which were more easily formed
than those by MCF-7/WT, as we showed previously. Therefore,
these data not only showed the connection between EMT features,
miR-489, and Smad3, but also revealed that miR-489 and Smad3
may participate in tumorigenesis, a critical step for metastasis.
To extend our ﬁndings into chemoresistance to other type of
drugs used clinically, we examined the expression of miR-489,
Smad3, and several EMT markers in breast cancer samples from
patients who had undergone anthracycline–taxane-based neoadju-
vant chemotherapy. Our result also showed a strong correlation of
miR-489–Smad3 with chemoresistance and EMT, suggesting the
general importance of miR-489 in chemoresistance.
In summary, we showed that loss of miR-489/gain of Smad3 is a
potential modulator of both chemoresistance and EMT-like proper-
ties in breast cancers. Therefore, re-expression of miR-489 or inhi-
bition of Smad3 might be potential therapeutic approaches for the
treatment of chemoresistant breast cancers.
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